<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F4C16084-C7EB-41B5-8A45-67FEF1DB66E6"><gtr:id>F4C16084-C7EB-41B5-8A45-67FEF1DB66E6</gtr:id><gtr:name>Pevion Biotech</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Wellcome Trust Centre for Human Genetics</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F4C16084-C7EB-41B5-8A45-67FEF1DB66E6"><gtr:id>F4C16084-C7EB-41B5-8A45-67FEF1DB66E6</gtr:id><gtr:name>Pevion Biotech</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/0D280345-7B21-43CF-8201-F54BA52AF661"><gtr:id>0D280345-7B21-43CF-8201-F54BA52AF661</gtr:id><gtr:firstName>Fiona</gtr:firstName><gtr:surname>Thompson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/51CB6BFA-15E9-4B5A-83BF-232DDFD9221F"><gtr:id>51CB6BFA-15E9-4B5A-83BF-232DDFD9221F</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Porter</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/17719B3D-8D27-40E3-967A-65E55AE07A99"><gtr:id>17719B3D-8D27-40E3-967A-65E55AE07A99</gtr:id><gtr:firstName>Adrian</gtr:firstName><gtr:surname>Hill</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0500634"><gtr:id>B472DCF6-EF47-41B5-878D-55638D73A4BE</gtr:id><gtr:title>Efficacy of combination malaria vaccines in human volunteers</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0500634</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2007-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>327637</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pevion Biotech</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>Pevion collaboration</gtr:description><gtr:id>378F87EB-F979-4DC6-A298-C2CF983A50E1</gtr:id><gtr:impact>The trial led to a clear but negative result for the combination and to the publication of several papers - see publication list.</gtr:impact><gtr:outcomeId>823997B7067-1</gtr:outcomeId><gtr:partnerContribution>Provision of a candidate vaccine for out clinical trials vaccine development programme</gtr:partnerContribution><gtr:piContribution>Rinaldo Zurbriggen and colleagues from Pevion provided their candidate malaria vaccine and we undertook a clinical trial of this in combination with one of our candidate malaria vaccines. The trial involved a sporozoite challenge component to assess vaccine efficacy.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>RDS public lecture, Dublin</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6B6A9AC3-6E87-4351-9AE5-D125D964D70F</gtr:id><gtr:impact>Public lecture entitled &amp;quot;Do It Yourself Vaccine Design&amp;quot;. See www.irishimmunology.ie/index.php?option=com_content&amp;amp;task=view&amp;amp;id=86&amp;amp;Itemid=49

award of ISI medal for public lecture</gtr:impact><gtr:outcomeId>DFB28C79D1B</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.irishimmunology.ie</gtr:url><gtr:year>2007</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>E63D16E0-1A56-40F8-8167-82D74628D8D3</gtr:id><gtr:title>Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3eed120722c68b490adeddd52dfc898c"><gtr:id>3eed120722c68b490adeddd52dfc898c</gtr:id><gtr:otherNames>Thompson FM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>A87649F8F5A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0048EC20-8572-4E88-87D1-2E9BCC54BE3E</gtr:id><gtr:title>Multiple functions of human T cells generated by experimental malaria challenge.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/07ce82a4218e6f71a50979e3ad3a107b"><gtr:id>07ce82a4218e6f71a50979e3ad3a107b</gtr:id><gtr:otherNames>Todryk SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>EE525077CA9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>30DA1C8E-DDDC-49F6-83C2-C3640EC212C0</gtr:id><gtr:title>Comparing human T cell and NK cell responses in viral-based malaria vaccine trials.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3da7b7941ef60f7b1128915d47c8c2a9"><gtr:id>3da7b7941ef60f7b1128915d47c8c2a9</gtr:id><gtr:otherNames>Berthoud TK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>7EBD1D8A596</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>073CAB58-C82C-40A1-A856-7ABEB678A6C3</gtr:id><gtr:title>MIG (CXCL9) is a more sensitive measure than IFN-gamma of vaccine induced T-cell responses in volunteers receiving investigated malaria vaccines.</gtr:title><gtr:parentPublicationTitle>Journal of immunological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3da7b7941ef60f7b1128915d47c8c2a9"><gtr:id>3da7b7941ef60f7b1128915d47c8c2a9</gtr:id><gtr:otherNames>Berthoud TK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1759</gtr:issn><gtr:outcomeId>DFA067E4A34</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1AD81C5C-5F24-4E24-9F86-5FD24420EFAB</gtr:id><gtr:title>Distinguishing malaria and influenza: early clinical features in controlled human experimental infection studies.</gtr:title><gtr:parentPublicationTitle>Travel medicine and infectious disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c7171b7961f3deba4f707f92470fada"><gtr:id>6c7171b7961f3deba4f707f92470fada</gtr:id><gtr:otherNames>Lillie PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1477-8939</gtr:issn><gtr:outcomeId>pm_16119_29_22531678</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E1EC277F-2BA8-40D7-8936-95781FD14514</gtr:id><gtr:title>The relationship between human effector and memory T cells measured by ex vivo and cultured ELISPOT following recent and distal priming.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/07ce82a4218e6f71a50979e3ad3a107b"><gtr:id>07ce82a4218e6f71a50979e3ad3a107b</gtr:id><gtr:otherNames>Todryk SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>7FDE0FC187C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B40F8E3C-8342-4CC1-A1CD-E6D9E58C1CC6</gtr:id><gtr:title>Comparison of clinical and parasitological data from controlled human malaria infection trials.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/058c1ccbe665a5aaa6371b395f1d2b02"><gtr:id>058c1ccbe665a5aaa6371b395f1d2b02</gtr:id><gtr:otherNames>Roestenberg M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_16119_29_22701640</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0500634</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>D8F3A27D-084A-40BB-A046-087DACE23410</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>3.4  Vaccines</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>